News Sentiment

RMD sentiment intelligence

ResMed Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 58 relevant articles
Exchange NYSE United States
Sector Healthcare Market context
Industry Medical Instruments & Supplies Read-through group
Latest close 203.87 Week of 10 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

82/100 classification confidence.

Company focus 58

directly relevant articles

Source quality 6

high-authority source matches

Trend context Trend inactive

-2.7% over one week, +4.7% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Positive

ResMed Inc. stock rises Wednesday, outperforms market

Market Reaction

Balanced read

61/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 82/100 classification
One-week reaction -2.7% Price reacting lower
Trend fit Trend inactive 4.7% over four weeks
Fair value -6.1% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 15
Neutral 33
Negative 10

Relevance

Why the article matched

Direct first
Direct company coverage 58
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Market source 12
Moomoo 5
simplywall.st 5
MarketWatch 4
Ad Hoc News 4
The Globe and Mail 3
TradingView 3
Simply Wall Street 2

Event Lens

What the news is about

Classified themes
Market update 35
Analyst action 9
Earnings 9
Macro sensitivity 2
Capital return 1
Deals and strategy 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 58
MarketWatch Direct company coverage

ResMed Inc. stock rises Wednesday, outperforms market

ResMed Inc. (RMD) stock increased by 2.88% to $198.57 on Wednesday, outperforming the broader market. This rise ended a three-day losing streak for the company's stock. The S&P 500 Index and the Dow Jones Industrial Average also saw gains on the same day.

Tone
Positive 76/100
Event
Market update
Published
15 Jul 2026 21:12
Source
MarketWatch
Moomoo Direct company coverage

Mizuho Adjusts Price Target on ResMed to $220 From $235, Maintains Outperform Rating

Mizuho has adjusted its price target for ResMed (RMD) to $220 from the previous $235, while maintaining an Outperform rating on the stock. The article also briefly mentions Unity Software's Q4 financial results, reporting revenue of $609 million which beat estimates, and a quarte

Tone
Negative 36/100
Event
Analyst action
Published
15 Jul 2026 16:12
Source
Moomoo
Morningstar Research Direct company coverage

Analyst Report: ResMed Inc.

Tone
Neutral 50/100
Event
Analyst action
Published
14 Jul 2026 23:34
Source
Morningstar Research
www.marketscreener.com Direct company coverage

Baird Adjusts ResMed Price Target to $217 From $225, Maintains Neutral Rating

Baird has adjusted its price target for ResMed (RMD) to $217 from $225, while retaining a Neutral rating on the stock. This update comes amidst other recent analyst adjustments for ResMed, including a downgrade from Citigroup and price target changes from Jefferies, Jarden, Wells

Tone
Negative 36/100
Event
Analyst action
Published
14 Jul 2026 12:10
Source
www.marketscreener.com
Moomoo Direct company coverage

ResMed Price Target Cut to $235.00/Share From $270.00 by Citigroup

Citigroup has significantly reduced its price target for ResMed (RMD) from $270.00 to $235.00 per share. This adjustment indicates a less optimistic outlook on the company's future stock performance by the financial institution.

Tone
Neutral 50/100
Event
Analyst action
Published
14 Jul 2026 10:39
Source
Moomoo
PR Newswire Direct company coverage

Cleveland Medical Devices Reports Favorable PTAB Outcomes in Five of Six ResMed IPR Challenges

Cleveland Medical Devices Inc. announced favorable outcomes in five out of six inter partes review (IPR) challenges filed by ResMed against its patents before the Patent Trial and Appeal Board (PTAB). In four cases, the PTAB found ResMed did not establish unpatentability, and in

Tone
Positive 65/100
Event
Market update
Published
13 Jul 2026 20:23
Source
PR Newswire
MarketWatch Direct company coverage

ResMed Inc. stock falls Monday, underperforms market

ResMed Inc. (RMD) shares dropped 2.63% to $198.50 on Monday, marking its second consecutive day of losses. This underperformance occurred during a generally poor trading session, with the S&P 500 Index (SPX) falling 0.79% and the Dow Jones Industrial Average (DJIA) declining 0.26

Tone
Negative 31/100
Event
Market update
Published
13 Jul 2026 16:58
Source
MarketWatch
Moomoo Direct company coverage

Citi Downgrades ResMed to Neutral From Buy; Price Target Is AU$34

Citi has downgraded ResMed (RMD) from Buy to Neutral, setting a price target of AU$34. This adjustment follows ongoing challenges related to the GLP-1 drug class impact on sleep apnea device sales and increased competitive pressure from new Chinese market entrants. While the long

Tone
Negative 31/100
Event
Analyst action
Published
13 Jul 2026 16:09
Source
Moomoo
Moomoo Direct company coverage

Citigroup Downgrades ResMed to Neutral From Buy, Adjusts Price Target to $235 From $270

Citigroup has downgraded ResMed (RMD) from a Buy rating to Neutral. Additionally, the firm adjusted its price target for ResMed, lowering it from $270 to $235. This change indicates a revised outlook on the stock's potential performance by Citigroup.

Tone
Neutral 50/100
Event
Analyst action
Published
13 Jul 2026 14:42
Source
Moomoo
Simply Wall Street Direct company coverage

3 US Healthcare Stocks Investors May Revisit As Inflation Pressures Build

As inflation pressures build and crude/polypropylene costs rise, investors are looking for defensive large-cap stocks. This article identifies three U.S. healthcare stocks—Abbott Laboratories (ABT), ResMed (RMD), and Stryker (SYK)—that offer essential products and services, makin

Tone
Positive 61/100
Event
Macro sensitivity
Published
13 Jul 2026 08:47
Source
Simply Wall Street
Quartr Direct company coverage

ResMed (RMD) Divestiture of MatrixCare presentation Summary

ResMed (RMD) has signed an agreement to divest its MatrixCare business to Frazier Healthcare Partners for $490 million, with the transaction expected to close in Q1 FY27. This strategic move aims to sharpen ResMed's focus on its core growth areas: sleep, breathing, and connected

Tone
Positive 67/100
Event
Market update
Published
11 Jul 2026 04:08
Source
Quartr
Market source Direct company coverage

Resmed Divests MatrixCare Business to Sharpen Focus on Connected Care

Resmed has agreed to sell its MatrixCare business to Frazier Healthcare Partners, a move aimed at focusing on higher-growth opportunities in sleep health, breathing health, and connected home-based care. The divestiture is expected to close in the first quarter of fiscal 2027 and

Tone
Positive 71/100
Event
Earnings
Published
10 Jul 2026 17:51
Source
Market source
MarketWatch Direct company coverage

ResMed Inc. stock falls Friday, underperforms market

ResMed Inc. (RMD) saw its stock fall by 2.20% on Friday, closing at $203.87, despite a positive day for the broader market with both the S&P 500 and Dow Jones Industrial Average rising. The company's stock is now 30.61% below its 52-week high reached on August 22nd.

Tone
Negative 29/100
Event
Market update
Published
10 Jul 2026 16:58
Source
MarketWatch
marketscreener.com Direct company coverage

Jefferies Adjusts Price Target on ResMed to $225 From $240

Jefferies has adjusted its price target on ResMed (RMD) to $225, down from $240. This change comes shortly after several other firms, including Jarden and Wells Fargo, also revised their price targets for the medical equipment company. ResMed recently announced the sale of its Ma

Tone
Negative 38/100
Event
Analyst action
Published
10 Jul 2026 12:38
Source
marketscreener.com
The Globe and Mail Direct company coverage

Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) Gets a Hold from Morgan Stanley

Morgan Stanley analyst David Bailey maintained a Hold rating on Resmed Inc (RMD). Bailey, a 4-star analyst, covers the Healthcare sector and has an average return of 7.0%. Resmed Inc's latest earnings report shows a quarterly revenue of A$1.42 billion and a net profit of A$395.1

Tone
Neutral 50/100
Event
Earnings
Published
10 Jul 2026 10:08
Source
The Globe and Mail
The Globe and Mail Direct company coverage

Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) Gets a Buy from Macquarie

Macquarie has maintained a Buy rating on Resmed Inc CHESS Depositary Interests (RMD) with a price target of A$46.60. This positive outlook is supported by recent earnings, which showed a quarterly revenue of A$1.42 billion and a net profit of A$395.1 million, an increase from the

Tone
Positive 72/100
Event
Earnings
Published
10 Jul 2026 01:01
Source
The Globe and Mail
TipRanks Direct company coverage

ResMed CEO Farrell Exercises Options and Trims Stake Under 10b5-1 Plan

ResMed CEO Michael J. Farrell exercised 4,991 stock options and subsequently sold the same number of shares under a Rule 10b5-1 trading plan for approximately $218.55 per share. Following these transactions, Farrell's direct holdings in ResMed decreased slightly to 466,223 shares

Tone
Neutral 50/100
Event
Deals and strategy
Published
09 Jul 2026 23:06
Source
TipRanks
Simply Wall Street Direct company coverage

ResMed (RMD) After Russell Growth Index Exits Is The Undervalued Narrative Still Intact

ResMed (RMD) has been dropped from several Russell growth indices, including the Russell 1000 Growth and Russell 3000 Growth, which has intensified scrutiny on the stock. Despite a recent share price decline of 15.9% year-to-date, Simply Wall St's analysis suggests ResMed is 21%

Tone
Positive 63/100
Event
Market update
Published
09 Jul 2026 20:57
Source
Simply Wall Street
Barchart.com Direct company coverage

ResMed's Q4 2026 Earnings: What to Expect

ResMed Inc. (RMD) is set to announce its fiscal Q4 2026 earnings, with analysts expecting an adjusted EPS of $2.90, marking a 13.7% increase year-over-year. Despite the positive outlook for earnings, ResMed's shares have underperformed the broader market, falling 18.7% over the p

Tone
Neutral 50/100
Event
Earnings
Published
09 Jul 2026 15:21
Source
Barchart.com
Market source Direct company coverage

Global Medical Ventilators Market Report 2025-2030 Just Released; Comprehensive Profiles of Getinge, Drägerwerk, Philips, Medtronic, and ResMed

This article announces the release of a new report on the global medical ventilators market, covering the period from 2025 to 2030. The report includes comprehensive profiles of key industry players such as Getinge, Drägerwerk, Philips, Medtronic, and ResMed. It is a market analy

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 14:15
Source
Market source
Investing.com Direct company coverage

ResMed chairman & CEO Michael Farrell sells $1.09m in company stock

ResMed's Chairman and CEO, Michael J. Farrell, sold $1.09 million worth of company stock through a Rule 10b5-1 trading plan, while simultaneously acquiring shares by exercising options. The transactions occurred on July 7, 2026, with Farrell selling 4,991 shares and exercising op

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 13:09
Source
Investing.com
Investing.com Canada Direct company coverage

Form 4 ResMed Inc For: 9 July By Investing.com

This article announces the filing of a Form 4 for ResMed Inc. on July 9, 2026. It provides a brief update on this financial market activity without offering further details within the main content. The article is primarily a placeholder for the Form 4 information, accompanied by

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 11:52
Source
Investing.com Canada
Stock Titan Direct company coverage

ResMed (RMD) CEO Michael Farrell sells 4,991 shares under 10b5-1 plan

ResMed (RMD) CEO Michael J. Farrell exercised stock options for 4,991 shares and subsequently sold them in open-market transactions under a Rule 10b5-1 plan. The sale occurred at a weighted average price of $218.5475 per share, totaling approximately $1.09 million. Following thes

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 11:40
Source
Stock Titan
MarketWatch Direct company coverage

ResMed Inc. stock falls Wednesday, underperforms market

Shares of ResMed Inc. (RMD) decreased by 6.33% to $205.84 on Wednesday, breaking a four-day winning streak. This fall occurred during a generally negative trading session, with the S&P 500 Index dropping 0.28% and the Dow Jones Industrial Average falling 1.09%.

Tone
Negative 29/100
Event
Market update
Published
08 Jul 2026 20:30
Source
MarketWatch
AlphaStreet Direct company coverage

Why ResMed Is Dropping 5.7%: RBC Capital Maintains Outperform

ResMed Inc. shares fell 5.7% after two Wall Street banks, RBC Capital and Wells Fargo, slashed their price targets on the medical device maker due to dimmer prospects for its sleep apnea and respiratory care products. RBC Capital maintained an Outperform rating but significantly

Tone
Negative 29/100
Event
Analyst action
Published
08 Jul 2026 19:13
Source
AlphaStreet